
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.
Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.
| Revenue (TTM) | $1.25B |
| Gross Profit (TTM) | $548.73M |
| EBITDA | $82.18M |
| Operating Margin | 5.91% |
| Return on Equity | 3.06% |
| Return on Assets | 1.52% |
| Revenue/Share (TTM) | $27.49 |
| Book Value | $28.32 |
| Price-to-Book | 1.17 |
| Price-to-Sales (TTM) | 1.31 |
| EV/Revenue | 1.122 |
| EV/EBITDA | 9.82 |
| Quarterly Earnings Growth (YoY) | 333.30% |
| Quarterly Revenue Growth (YoY) | 7.50% |
| Shares Outstanding | $45.48M |
| Float | $44.38M |
| % Insiders | 2.15% |
| % Institutions | 109.10% |
Volatility is currently expanding

OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OMCL and any ticker you trade — then tracks every position and per-strategy win rate.